Design, sequential synthesis, kinase inhibitors comparative docking, MD simulations, 99mTc-coupling and in-vivo studies of novel pyrazolopyrimidine derivatives

Document Type : Original Article

Authors

1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Helwan, Cairo, Egypt.

2 Pharmaceutical Chemistry Department, Faculty of Pharmacy, MSA University, Cairo, Egypt

3 Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, 13759, Cairo, Egypt

4 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Egypt

5 Heliopolis University

6 Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo 13759, Egypt.

Abstract

Pyrazolopyrimidine derivative was synthesized and labeled with 99mTc using sodium dithionite as reducing agents. The purity of radiochemical 99mTc(Na2S2O4)-compound was 93.4%, and the synthesized complex was stable in vitro for 6 hours. Furthermore, using a radiolabeling technique, a bio-distribution investigation showed that tumor-bearing mice exhibited a remarkable absorption of [99mTc]Tc-complex, with a significant concentration in tumor tissues and a T/NT of 6.58 after 60 minutes after injection. These encouraging results mean that the synthesized compound offers a potential radio-carrier that can be used as a tumor marker and, following additional preclinical research, can be used for cancer therapy. Molecular dynamic simulation confirmed the stability of this compound in the active sites of both EGFR and VEGFR-2 receptors.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 29 August 2024
  • Receive Date: 09 July 2024
  • Revise Date: 29 August 2024
  • Accept Date: 29 August 2024